Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Rituximab in Young, Fit CLL Patients (VeRiTAs)
NCT03455517Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by GIMEMA. Primary endpoint: Complete Response at 15 months. Started Oct 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03455517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455517.